Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Draft Biosimilar Red Tape Elimination Act: Pharmacist As Ally, Would Patients Benefit?

What's The Generics Experience?

Executive Summary

If the bill on the Biosimilar Red Tape Elimination Act is passed, all biosimilars would be deemed interchangeable on US FDA approval. Scrip takes a look at what empowering pharmacists could mean, what the generics substitution experience shows and where possible pain points lie

You may also be interested in...



Data Exclusivity Demand In EFTA-India Deal: Access, Licensing, Other Implications

The contentious issue of data exclusivity came to the fore during the European Free Trade Association's negotiations with India for a Free Trade Agreement. What are the arguments in support and against, including impact on compulsory and voluntary licensing?

A Decade At The Top: Lupin MD On Listing Adjacencies, Creating Healthcare Continuum

As family-led firms go through a churn in India, Lupin’s MD Nilesh Gupta speaks about adding value via adjacencies to the legacy business, building digital interfaces and a healthcare continuum for patients. In an interview with Scrip, he also emphasized Lupin promoters are neither interested in selling their own stake nor in acquiring that of Cipla’s promoters.

Video Roundtable: APAC Team Talks Key Regional Trends And Topics

Join the Pink Sheet's APAC content team for a video overview of major trends and topics in the regional biopharma industry over the past few months.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148944

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel